Neugebauer Maximilian, Grundmann Clara E, Lehnert Michael, von Stetten Felix, Früh Susanna M, Süss Regine
Hahn-Schickard, Georges-Koehler-Allee 103, 79110 Freiburg, Germany.
Laboratory for MEMS Applications, IMTEK-Department of Microsystems Engineering, University of Freiburg, Georges-Koehler-Allee 103, 79110 Freiburg, Germany.
Pharmaceutics. 2022 Jun 25;14(7):1348. doi: 10.3390/pharmaceutics14071348.
RNA interference (RNAi) is a powerful therapeutic approach for messenger RNA (mRNA) level regulation in human cells. RNAi can be triggered by small interfering RNAs (siRNAs) which are delivered by non-viral carriers, e.g., dendriplexes. siRNA quantification inside carriers is essential in drug delivery system development. However, current siRNA measuring methods either are not very sensitive, only semi-quantitative or not specific towards intact target siRNA sequences. We present a novel reverse transcription real-time PCR (RT-qPCR)-based application for siRNA quantification in drug formulations. It enables specific and highly sensitive quantification of released, uncomplexed target siRNA and thus also indirect assessment of siRNA stability and concentration inside dendriplexes. We show that comparison with a dilution series allows for siRNA quantification, exclusively measuring intact target sequences. The limit of detection (LOD) was 4.2 pM (±0.2 pM) and the limit of quantification (LOQ) 77.8 pM (±13.4 pM) for uncomplexed siRNA. LOD and LOQ of dendriplex samples were 31.6 pM (±0 pM) and 44.4 pM (±9.0 pM), respectively. Unspecific non-target siRNA sequences did not decrease quantification accuracy when present in samples. As an example of use, we assessed siRNA complexation inside dendriplexes with varying nitrogen-to-phosphate ratios. Further, protection of siRNA inside dendriplexes from RNase A degradation was quantitatively compared to degradation of uncomplexed siRNA. This novel application for quantification of siRNA in drug delivery systems is an important tool for the development of new siRNA-based drugs and quality checks including drug stability measurements.
RNA干扰(RNAi)是一种用于调节人类细胞中信使核糖核酸(mRNA)水平的强大治疗方法。RNAi可由小分子干扰RNA(siRNA)触发,这些小分子干扰RNA由非病毒载体(如树枝状聚合物)递送。在药物递送系统开发中,载体内部siRNA的定量至关重要。然而,目前的siRNA测量方法要么不太灵敏,只是半定量的,要么对完整的靶标siRNA序列缺乏特异性。我们提出了一种基于新型逆转录实时定量聚合酶链反应(RT-qPCR)的方法,用于药物制剂中siRNA的定量。它能够对释放的、未复合的靶标siRNA进行特异性和高灵敏度的定量,从而间接评估树枝状聚合物内部siRNA的稳定性和浓度。我们表明,与稀释系列进行比较可实现siRNA定量,专门测量完整的靶标序列。对于未复合的siRNA,检测限(LOD)为4.2 pM(±0.2 pM),定量限(LOQ)为77.8 pM(±13.4 pM)。树枝状聚合物样品的LOD和LOQ分别为31.6 pM(±0 pM)和44.4 pM(±9.0 pM)。当样品中存在非特异性非靶标siRNA序列时,不会降低定量准确性。作为应用实例,我们评估了不同氮磷比的树枝状聚合物内部的siRNA复合情况。此外,还定量比较了树枝状聚合物内部的siRNA与未复合的siRNA被核糖核酸酶A降解的情况。这种用于药物递送系统中siRNA定量的新方法是开发新型基于siRNA的药物和包括药物稳定性测量在内的质量检查的重要工具。